PMID- 34492128
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20220731
IS  - 1097-0045 (Electronic)
IS  - 0270-4137 (Print)
IS  - 0270-4137 (Linking)
VI  - 81
IP  - 15
DP  - 2021 Nov
TI  - Pathological significance and prognostic role of LATS2 in prostate cancer.
PG  - 1252-1260
LID - 10.1002/pros.24226 [doi]
AB  - BACKGROUND: Large tumor suppressor 2 (LATS2) is an important regulator of the 
      Hippo pathway and it plays crucial roles in cell survival and behaviors. Herein, 
      we evaluated the pathological roles of LATS2 in prostate cancer (PC), for which 
      very little information is available. METHODS: Cell proliferation, migration, and 
      invasion in response to the siRNA-mediated knockdown (KD) LATS2 expression were 
      evaluated in two PC cell lines (LNCaP and PC3). The expression of LATS2 in 
      specimens from 204 PC patients was investigated immunohistochemically, and the 
      relationships between its expression and clinicopathological features, 
      proliferation index (PI; measured using an anti-KI-67 antibody), and biochemical 
      recurrence (BCR) were investigated. RESULTS: KD of LATS2 increased the growth, 
      migration, and invasion in LNCaP cells and only increased migration in PC3 cells. 
      The expression of LATS2 was negatively associated with the grade group, T, N, M 
      stage, and PI. In addition, the expression of LATS2 was a useful predictor of the 
      histological effects of neoadjuvant hormonal therapy and BCR-free survival 
      periods. A multivariate analysis model including clinicopathological features 
      showed that negative expression of LATS2 had a significantly higher risk of BCR 
      (odds ratio = 2.95, P < 0.001). CONCLUSIONS: LATS2 acts as a tumor suppressor in 
      PC. LATS2 expression is a useful predictor for BCR. LATS2-related activities are 
      possibly dependent on the androgen-dependency of PC cells. Therefore, we suggest 
      that LATS2 could be a potential therapeutic target and a useful predictor for 
      outcome in patients with PC.
CI  - (c) 2021 The Authors. The Prostate published by Wiley Periodicals LLC.
FAU - Matsuda, Tsuyoshi
AU  - Matsuda T
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Miyata, Yasuyoshi
AU  - Miyata Y
AUID- ORCID: 0000-0001-6272-6657
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Nakamura, Yuichiro
AU  - Nakamura Y
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Otsubo, Asato
AU  - Otsubo A
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Mukae, Yuta
AU  - Mukae Y
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Harada, Junki
AU  - Harada J
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Mitsunari, Kensuke
AU  - Mitsunari K
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Matsuo, Tomohiro
AU  - Matsuo T
AUID- ORCID: 0000-0002-9508-0319
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Ohba, Kojiro
AU  - Ohba K
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
FAU - Furusato, Bungo
AU  - Furusato B
AD  - Department of pathology, Nagasaki University Graduate School of Biomedical 
      Scieneces, Nagasaki, Japan.
FAU - Sakai, Hideki
AU  - Sakai H
AD  - Department of Urology, Nagasaki University Graduate School of Biomedical 
      Sciences, Nagasaki, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210907
PL  - United States
TA  - Prostate
JT  - The Prostate
JID - 8101368
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.7.1.11 (LATS2 protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Movement/physiology
MH  - Cell Proliferation/*physiology
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Prognosis
MH  - Prostatic Neoplasms/genetics/*metabolism/pathology
MH  - Protein Serine-Threonine Kinases/genetics/*metabolism
MH  - RNA, Small Interfering
MH  - Tumor Suppressor Proteins/genetics/*metabolism
PMC - PMC9290072
OTO - NOTNLM
OT  - LATS2
OT  - biochemical recurrence
OT  - malignant aggressiveness
OT  - prostate cancer
OT  - tumorigenesis
COIS- The authors declare no conflict of interest.
EDAT- 2021/09/08 06:00
MHDA- 2022/02/25 06:00
PMCR- 2022/07/18
CRDT- 2021/09/07 17:29
PHST- 2021/04/27 00:00 [revised]
PHST- 2021/03/11 00:00 [received]
PHST- 2021/04/30 00:00 [accepted]
PHST- 2021/09/08 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2021/09/07 17:29 [entrez]
PHST- 2022/07/18 00:00 [pmc-release]
AID - PROS24226 [pii]
AID - 10.1002/pros.24226 [doi]
PST - ppublish
SO  - Prostate. 2021 Nov;81(15):1252-1260. doi: 10.1002/pros.24226. Epub 2021 Sep 7.